[ad_1]
OTTAWA, Ontario, Might 30, 2022–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences company centered on growing and commercializing merchandise for livestock, companion animal and human purposes that safely enhances feed consumption and helps immune operate, thereby supporting normal well being and efficiency, is happy to announce that it has signed a brand new distribution settlement with Nong San Viet Co., Ltd (VIET ACC) to assist the corporate’s continued market enlargement for its oxidized carotenoid-based feed additive product in Vietnam.
Based in 2005, VIET ACC has established itself as a premier distributor of main feed elements and feed additive manufacturers to main producers all through Vietnam. With a major deal with poultry and swine, the corporate is a pacesetter within the distribution of premix and feed components, in addition to within the buying and selling of agricultural commodities to be used in livestock and aquaculture.
“Vietnam represents vital market alternative for Avivagen, and we’re excited to be working with Viet ACC to raised entry the biggest feed market in Southeast Asia,” says Kym Anthony, Chief Govt Officer, Avivagen. “We’ve seen robust curiosity from producers throughout Vietnam since receiving regulatory approval earlier this yr and hope to see equally robust outcomes from this new relationship over the approaching months and years.”
Vietnam represents the biggest feed market in Southeast Asia in response to a report by the US Grains Council, which signifies whole annual feed consumption of over 32 MMT in 2020. Moreover, The Grains Council report states that Vietnam is a robust progress market which is anticipated to surpass 35 MMT of feed inside the subsequent few years.i Manufacturing inside the nation is dominated by swine, with feed for swine accounting for about 38% of whole feed, adopted by poultry accounting for 21.6% of whole feed. (2020)ii.
About Avivagen
Avivagen is a life sciences company centered on growing and commercializing merchandise for livestock, companion animal and human purposes that, by safely supporting immune operate, promote normal well being and efficiency. It’s a public company traded on the TSX Enterprise Alternate below the image VIV and is headquartered in Ottawa, Canada, primarily based in partnership amenities of the Nationwide Analysis Council of Canada. For extra info, go to www.avivagen.com. The contents of the web site are expressly not integrated by reference on this press launch.
About OxC-beta™ Expertise and OxC-beta™ Livestock
Avivagen’s OxC-beta™ expertise is derived from Avivagen discoveries about β-carotene and different carotenoids, compounds that give sure vegetables and fruit their shiny colors. By means of assist of immune operate, the expertise offers a non-antibiotic technique of selling well being and progress. OxC-beta™ Livestock is a proprietary product proven to be an efficient and financial different to the antibiotics generally added to livestock feeds. The product is at present accessible on the market in the USA, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.
Avivagen’s OxC-beta™ Livestock product is protected, efficient and will fulfill the worldwide mandate to take away all in-feed antibiotics as progress promoters. Quite a few worldwide livestock trials with poultry and swine utilizing OxC-beta™ Livestock have confirmed that the product performs in addition to, and, typically, in some features, higher than in-feed antibiotics.
Ahead Wanting Statements
This information launch contains sure forward-looking statements which can be primarily based upon the present expectations of administration. Ahead-looking statements contain dangers and uncertainties related to the enterprise of Avivagen Inc. and the surroundings through which the enterprise operates. Any statements contained herein that aren’t statements of historic details could also be deemed to be forward-looking, together with these recognized by the expressions “intention”, “anticipate”, “seem”, “consider”, “take into account”, “might”, “estimate”, “anticipate”, “if”, “intend”, “objective”, “hope”, “doubtless”, “could”, “plan”, “presumably”, “doubtlessly”, “pursue”, “appear”, “ought to”, “whether or not”, “will”, “would” and related expressions.
Statements set out on this information launch referring to the long run progress and prospects for Avivagen and the chance for OxC-beta™ Livestock to exchange antibiotics in livestock feeds as progress promoters are forward-looking statements. These forward-looking statements are topic to quite a lot of dangers and uncertainties that would trigger precise outcomes or occasions to vary materially from present expectations. As an example, Avivagen’s merchandise could not acquire market acceptance or regulatory approval in new jurisdictions or for brand spanking new purposes and will not be extensively accepted as a alternative for antibiotics as progress promoters in livestock feeds on account of many components, a lot of that are exterior of Avivagen’s management. Readers are referred to the chance components related to the enterprise of Avivagen set out in Avivagen’s most up-to-date administration’s dialogue and evaluation of economic situation accessible at www.SEDAR.com. Besides as required by regulation, Avivagen assumes no obligation to replace the forward-looking statements, or to replace the the reason why precise outcomes might differ from these mirrored within the forward-looking statements.
Neither TSX Enterprise Alternate nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Alternate) accepts accountability for the adequacy or accuracy of this launch.
Copyright © 2022 Avivagen Inc.
________________________________
ihttps://grains.org/markets-tools-data/markets/market-profiles/vietnam/
iihttps://public.tableau.com/app/profile/alltech.digital/viz/AlltechGlobalFeedSurvey2021/AlltechGlobalFeedSurvey2021
View supply model on businesswire.com: https://www.businesswire.com/information/house/20220530005017/en/
Contacts
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Cellphone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Chief Govt Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Workplace Cellphone: 613-949-8164
Web site: www.avivagen.com
[ad_2]
Source link
